Paper: Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia
In a retrospective review of 188 patients treated with CPX-351 in 25 German centers the median overall survival was 21 months, significantly longer than the 9.5 months seen in the CPX arm in the phase III clinical trial by Lancet et. al.
The patients in this group were a little younger, a higher number of patients had t-AML, and a very high percentage went on to transplant (62% vs 34% in the Phase III trial). We have seen in prior analysis that the biggest benefit in CPX-351 is attained by those who go on to transplant and this likely explains the better outcomes. Subgroup analysis suggests worse outcomes in those with prior HMA exposure, but we don’t know what percent of patients received prior HMA, I look forward to hopefully seeing that data at the oral abstract presentation.
